India Grants First Compulsory License To Natco For Bayer’s Nexavar; Disappointed, Bayer May Challenge Decision
This article was originally published in PharmAsia News
Executive Summary
India grants compulsory license to Natco for Bayer’s Nexavar; ruling could start run on more CLs.
You may also be interested in...
Bayer Says India's Natco Has No Ground For Compulsory License; Blames Lack of Drug Availability On Poor Health Infrastructure
MUMBAI - As Natco Pharma Ltd. is set to test the viability of India's highly debated compulsory licensing provisions by challenging Bayer AG's kidney and liver cancer treatment Nexavar (sorafenib), the German polymers-to-pharmaceuticals conglomerate has said that "extensive use of compulsory licenses will in the long-term undermine and threaten the patent system.
Cipla Targets Merck's Leading Anti-HIV Brand Isentress; Applies For Voluntary License In India
MUMBAI - Merck & Co.'s HIV integrase inhibitor Isentress (raltegravir) may have been a big success across many markets, but in India the anti-AIDS drug may be short of its mark. Leading home-grown company Cipla Ltd. has taken the route of applying for a "voluntary license" for the drug to New Jersey-headquartered Merck because Cipla says it is not reaching needy patients in India and it is priced exorbitantly
Indian Compulsory License Debate Enters New Phase With Push From Local Pharma Natco
MUMBAI - In a move that could have far-reaching impact in determining India's approach to compulsory licensing, Natco Pharma - the local oncology and anti-HIV drugs specialist - has written to German drugs-to-agrochemicals giant Bayer to provide it with a "voluntary license" to manufacture and market its anti-cancer drug brand Nexavar (sorafenib)